Omega 3 Fish Oil
Thousands of studies have been done over the years on Omega 3 fish oil.
- Protecting against coronary heart disease and stroke
- Promoting brain development in infants and toddlers. Improving brain health in adults
- Promoting healthy skin and helping with skin disorders like acne and psoriasis
- Helping autoimmune disorders
- Helping with Crohn disease
- Protecting against cancers: breast, colon, and prostate
- Helping to alleviate rheumatoid arthritis aches and pains (due to anti-inflammatory content)
- Reducing cholesterol levels
SAN DIEGO, March 10, 2020 /PRNewswire/ — Medical Marijuana, Inc. (OTC: MJNA) (the “Company”), the first-ever publicly traded cannabis company in the United States that launched the world’s first-ever cannabis-derived nutraceutical products, brands and supply chain, today announced that its subsidiary Kannaway® has launched a new cannabidiol (CBD) product, its Hemp + Calm Oral Applicator, in Europe. This product is the Company’s first product available in Europe that is made using its Blue Label Real Scientific Hemp Oil™ (RSHO™).
“Europe has proven to be our largest market since we launched across the continent in 2018,” said Dr. Stuart Titus, CEO of Medical Marijuana, Inc. “As the European CBD market continues to grow exponentially, we intend to continue innovating and launching new products that fit the needs of European consumers.”
Each Kannaway® Hemp + Calm Oral Applicator contains 2,000 mg of CBD from broad-spectrum hemp oil. The CBD used in the product is derived from non-GMO hemp, scientifically extracted using a solvent-free CO2 process, and quality-certified through the Company’s Triple Lab Testing® process to deliver the potential natural benefits of hemp CBD.
According to the Brightfield Group, the CBD market in Europe is expected to grow over 400 percent by 2023. Kannaway® is the first direct selling company to legally offer hemp-based CBD wellness products to the entire European market.
Information on Kannaway® in Europe or on how to become a European Kannaway® Brand Ambassador can be found at https://kannaway.com/.
Kannaway® is a network sales and marketing company specializing in the sales and marketing of hemp-based botanical products. Kannaway currently hosts weekly online sales meetings and conferences across the United States, offering unique insight and opportunity to sales professionals who are desirous of becoming successful leaders in the sale and marketing of hemp-based botanical products.
About Medical Marijuana, Inc.
We are a company of firsts®. Medical Marijuana, Inc. (MJNA) is a cannabis company with three distinct business units in the non-psychoactive cannabinoid space: a global portfolio of cannabinoid-based nutraceutical brands led by Kannaway® and HempMeds®; a pioneer in sourcing the highest-quality legal non-psychoactive cannabis products derived from industrial hemp; and a cannabinoid-based clinical research and botanical drug development sector led by its pharmaceutical investment companies and partners including AXIM® Biotechnologies, Inc. and Kannalife, Inc. Medical Marijuana, Inc. was named a top CBD producer by CNBC. Medical Marijuana, Inc. was also the first company to receive historic import permits for CBD products from the governments of Brazil, Mexico, Argentina, and Paraguay and is a leader in the development of international markets. The company’s flagship product Real Scientific Hemp Oil has been used in several successful clinical studies throughout Mexico and Brazil to understand its safety and efficacy.
Medical Marijuana, Inc.’s headquarters is in San Diego, California, and additional information is available at OTCMarkets.com or by visiting www.medicalmarijuanainc.com. To see Medical Marijuana, Inc.’s corporate video, click here.
Shareholders and consumers are also encouraged to buy CBD oil and other products at Medical Marijuana, Inc.’s shop.
This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of Medical Marijuana, Inc. to be materially different from the statements made herein.
FOOD AND DRUG ADMINISTRATION (FDA) DISCLOSURE
These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.
Medical Marijuana, Inc. does not sell or distribute any products that are in violation of the United States Controlled Substances Act.
Investor Relations Contact:
P. (858) 283-4016
View original content to download multimedia: http://www.prnewswire.com/news-releases/medical-marijuana-inc-subsidiary-kannaway-launches-new-hemp–calm-cbd-oral-applicator-in-europe-301020463.html
SOURCE Medical Marijuana, Inc.
CBD hemp, a new crop in Connecticut, might make farmers between $5,000 and nearly $12,000 per acre, according to a report from UConn’s Zwick Center for Food and Resource Policy and Department of Agricultural and Resource Economics.
The research study is the first of its kind to measure costs and returns for CBD hemp in Connecticut. Since the death of the 2019 Farm Expense, farmers have been eager to grow the crop to meet industry demand for cannibidiol or CBD, a chemical substance that has acquired popularity in a wide array of items over the previous several years.
Jeremy Jelliffe, a scientist in the Department of Agricultural and Resource Economics in the College of Agriculture, Natural Resources, and Health was lead author on the research study. He states the critical requirement for the report emerged in the spring of 2019.
” Hemp growing has actually been restricted for so long and as a result there has been restricted research study and details on it,” Jelliffe says. “Considering that Connecticut authorized the pilot program so growers could start growing in 2019, there was a call for additional info.”
Jelliffe describes this report focuses just on the financial practicality of CBD hemp farming. Hemp and cannabis are the very same plant, Marijuana sativa. What distinguishes whether a plant is considered hemp or marijuana is the level of tetrahydrocannabinol (THC) it contains. With the growing variety of applications for CBD catching attention in the medical neighborhood, there is presently a high need for CBD hemp.
But as with any brand-new crop, there’s a lot that requires to be found out by farmers, from best practices to overall financial practicality. The report tries to fill some of these understanding gaps by taking a full take a look at the crop, from the cost of startup, to the expense of growing the crop, and the prospective returns.
” The first portion of the report is straightforward, we developed a budget model comparable to if we were going to start our own hemp production,” Jelliffe says. “We looked at the suggested innovations from agronomists,” says Jelliffe.
Jelliffe authored the report with professor Rigoberto Lopez and UConn extension teacher Shuresh Ghimire, who has actually been working carefully with the first wave of hemp growers in the state.
The researchers identified good management practices to provide a model that growers can reference, Jelliffe says.
” What we provide is a little different than what I would think of as normal growing practices today but what we expect to end up being more extensively embraced. Some practices we present include utilizing plasticulture, drip watering, fencing, things that not everyone did (in the 2019 growing season) however after the first season I think more people will be inclined to do,” he states.
Jelliffe says the full report details requirements coming out of various research study hubs from around the nation.
” Other researchers have actually been looking at hemp intensively over the last several years, given that the last Farm Expense from2014 With this report we include information from other reports to give more information to the growers. In terms of cost and returns the truth sheet has a really nice summary,” says Jelliffe.
The scientists estimate that it costs about $19,000 per acre to grow hemp, including $6,570 in repaired costs and $12,719 in variable costs, implying expenses that change with the level of production. The yield per acre depends on numerous variables, such as local costs, CBD material, and overall dried flower collected.
At the dominating regional cost, farmers can expect to make approximately $24,375 in earnings per acre, for a profit of in between $5,086 and $11,656, depending upon those variable expenses
” Ultimately,” the scientists compose, “the profitability of this enterprise will depend on technical capabilities of individual farmers (yield and CBD content) as well as external market forces, predominately CBD rates.”
” We are approximating that the local cost will continue to drop this year with the large supply that is out there, and best case, we will see a price of one dollar and twenty-five cents per pound, per portion of CBD, per acre,” says Jelliffe.
Though the rate is not as high as some had actually hoped at the beginning of the 2019 growing season, Jelliffe says he thinks that farmers are concerning deal with the reality in the market.
” The ones who make the most money are the ones who can do it most effectively, produce the very best quality, and market it at a premium. Farmers understand that is how it works no matter what the crop is and they are all trying to produce the best they can. They stabilize this with the price they expect to be able to get.”
Jelliffe is enthusiastic the report will assist farmers get the most out of their growing enterprises.
” It has been exciting to work with Connecticut growers that are learning more about this brand-new crop and how to best grow it,” he states. “I think there is a lot of capacity for profitability however I likewise think there is a great deal of danger and unpredictability that we have seen with the drop in rates. Eventually it is going to take some time for those who are really dedicated to this new crop to figure it out.”.
The numbers on Connecticut’s newest crop: CBD hemp (2020, April 3).
retrieved 3 April2020
from https://phys.org/news/2020-04- connecticut-crop-cbd-hemp. html.
This file is subject to copyright. Apart from any reasonable dealing for the function of personal study or research study, no.
part may be replicated without the composed approval. The content is offered information purposes only.
Cronos Group (NASDAQ:CRON) was originally scheduled to report its Q4 results on Feb. 27, 2020. However, the company delayed this update because of a review by the Audit Committee of its board of directors into the recognition of revenue related to wholesale bulk resin purchases and sales.
It took a while, but Cronos Group finally joined its peers in reporting its results for the quarter ending Dec. 31, 2019. The Canadian cannabis producer announced its 2019 fourth-quarter and full-year results after the market closed on Monday.
Unsurprisingly, Cronos said that it would need to restate its financial results for the first, second, and third quarters of 2019 based on the committee’s findings. But there were several surprises in Cronos’ Q4 update, including these three, in particular.
Image source: Getty Images.
1. Major revenue shortfall
Analysts surveyed by Zacks expected Cronos to report Q4 net revenue of $12.5 million. The company announced actual Q4 net revenue of only $7.3 million — well below what analysts were looking for.
Cronos Group’s Q4 net revenue reflected a 71% year-over-year jump. However, its revenue was lower than the $7.64 million recorded in the previous quarter (after its restatement of revenue).
The company reported $2.7 million in revenue during the fourth quarter from its U.S. segment, which consists of the Redwood business acquired last year. Cronos’ rest of world segment, which includes its core business in the Canadian cannabis market, generated Q4 net revenue of $4.6 million.
2. A tidy profit (but don’t get excited about it)
While Cronos Group’s top line disappointed, the company reported a profit of $61.6 million, or $0.16 per diluted share. The consensus analysts’ estimate was for a loss of $0.04 per share. But don’t get too excited about this surprise.
The only reason behind Cronos’ positive bottom line was that the company recorded a gain of $118.8 million on the revaluation of derivative liabilities associated with Altria‘s (NYSE:MO) investment. This accounting gain stemmed from Cronos Group stock sinking during the fourth quarter.
A better number to look at to determine how Cronos fared in Q4 is its adjusted earnings before interest, taxes, depreciation, and amortization (EBITDA). The company posted an adjusted EBITDA loss in Q4 of $51.9 million, a significant deterioration from the adjusted EBITDA losses of $5.8 million in the prior-year period.
3. CBD pause
In November, Cronos Group CEO Michael Gorenstein spoke excitedly in the company’s Q3 conference call about the launch of its new PEACE+ hemp-derived CBD tinctures in the U.S. market. He said that Cronos would use Altria’s sales and distribution network to build sales for its hemp CBD products.
That was then. On Monday, Cronos stated that it decided to “pause” the distribution of PEACE+ CBD tinctures through Altria’s sales and distribution network. The company said that it “will continue to evaluate other product formats and categories that we believe may be more suitable for the PEACE+ brand in the evolving environment.”
The main issue for Cronos Group right now is the same one that impacts nearly every company in North America and across the world: the novel coronavirus pandemic. All of Cronos’ facilities remain in operation, though. Cannabis has been designated as an essential business in areas where the company operates. However, Cronos acknowledged that it could be impacted by the COVID-19 crisis.
This viral outbreak will likely dampen the anticipated growth in Canada’s Cannabis 2.0 market for cannabis derivatives products over the short term. As a result, Cronos’ revenue growth in 2020 could be a lot lower than hoped.
But the company claims something that most marijuana stocks don’t, namely a strong balance sheet. Thanks to Altria’s investment, Cronos’ cash stockpile totaled $1.5 billion at the end of 2019. That should be more than enough for the company to weather the storm caused by COVID-19.
Editor’s note: A previous version of this article incorrectly referenced Cronos Group’s financial results in Canadian dollars instead of U.S. dollars. The Fool regrets the error.
Keith Speights has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.”>
United States Hemp Derivatives (Hemp-Derived CBD, Hemp Seed Oil, Hemp Fiber, Others) Market Insights, 2018-2027
DUBLIN–(BUSINESS WIRE)–The “US Hemp Derivatives Market to 2027 – Country Analysis and Forecasts by Type; Application” report has been added to ResearchAndMarkets.com’s offering.
The US hemp derivatives market was valued at US$ 1,403.5 million in 2018, and it is expected to grow at a CAGR of 23.7% during the forecast period 2019-2027 to reach US$ 7,056.4 million by 2027.
Increasing consumer awareness regarding the nutritional benefits related to hemp derivatives and growing cultivation of industrial hemp has driven the growth of US hemp derivatives market. Hemp derivatives such as CBD, seed oil, fibers etc. find vast applications in several end-use industries such as food and beverage, pharmaceuticals, personal care, animal feed, and others, which is further driving the demand of the market. The trend of hemp-based food and beverages is gaining popularity in the US thus manufacturers are investing heavily in this market.
Based on the type, the US hemp derivatives market has been segmented into hemp-derived CBD, hemp fibers, hemp seed oil, and others. In 2018, Hemp-Derived CBD have led the US hemp derivatives market.
Cannabidiol (CBD) is a compound extracted from the leaves, stalks, and flowers of the hemp plant. Due to the low presence of THC (0.3%), an intoxicating compound that is present in marijuana, hemp can be utilized for extracting CBD, which in turn can be infused into various pharmaceutical products and supplements. Hemp-derived CBD provides broad-spectrum nutrition, offering a complex biochemical matrix of many constituents working synergistically. These compounds include phytocannabinoids, essential fatty acids, terpenes, plant sterols, chlorophyll, and vitamin E.
CBD is a popular natural remedy used for many common diseases due to the absence of psychoactive effects. It is promoted as a treatment for a range of conditions, including epileptic seizures, post-traumatic stress disorder, anxiety and depression, diabetes prevention, alleviation of cancer symptoms, and inflammation. It is also utilized in a range of consumer products such as food and beverages (syrups and gummies) and dietary supplements (pills and capsules). Increasing demand for CBD-infused products such as dietary supplements and other pharmaceutical products among the consumer is expected to drive the growth of hemp-derived CBD during the forecast period.
The US hemp derivatives market has witnessed a significant growth owing to factors such as increasing consumer awareness regarding the nutritional benefits related to hemp derivatives and growing cultivation of industrial hemp. The hemp derivatives find its applications in several end-use industries such as food and beverage, pharmaceuticals, personal care, and animal feed, which is further driving the demand of the market. Significant growth in the demand for hemp-based food products in US is also adding inputs to the growth of the US hemp derivatives market. However, the hemp derivatives market in the US is highly depend upon the imports from another country such as Canada, China and European countries (France, Germany, Hungary, Italy). Nevertheless, with the growing demand for hemp derivatives form personal care and food & beverages industries, market players have the opportunity to invest in this market.
Canada Hemp Foods Ltd, Colorado Hemp Works, LLC, Hempco Food and Fiber Inc., Z-Company BV, Bell Flavors & Fragrances Inc., Neptune Wellness Solutions, Inc., Radient Technologies, Aurora Cannabis Inc., Re Botanicals, Inc., Aphria Inc. are amongst the key market players operating in the US hemp derivatives market.
Reasons to Buy
- Highlights key business priorities in order to assist companies to realign their business strategies.
- The key findings and recommendations highlight crucial progressive industry trends in the US hemp derivatives, thereby allowing players to develop effective long term strategies.
- Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
- Scrutinize in-depth the market trends and outlook coupled with the factors driving the market, as well as those hindering it.
- Enhance the decision-making process by understanding the strategies that underpin commercial interest with respect to products, segmentation and industry verticals.
Key Topics Covered
1.1 Scope of the Study
1.2 Report Guidance
1.3 Market Segmentation
1.3.1 US Hemp Derivatives Market, by Type
1.3.2 US Hemp Derivatives Market, by Application
2. Key Takeaways
3. Research Methodology
3.2 Secondary Research
3.3 Primary Research
4. US Hemp Derivatives Market – Key Industry Dynamics
4.1.1 Growing Demand for Hemp Derivatives from Several End-use Industries
4.1.2 Legalization in Cultivation of Hemp
4.2.1 High Dependence on Imports of Hemp as a Raw Material
4.3.1 Growth of Food and Beverage Industry
4.4.1 Adoption of Hemp Derivatives by Cosmetic Industry
4.5 Impact Analysis of Drivers and Restraints
5. US Hemp Derivatives – Market Analysis
5.1 US Hemp Derivatives Market Overview
5.2 US Hemp Derivatives Market Forecast and Analysis
5.3 Market Positioning – Key Market Players
6. US Hemp Derivatives Market – By Type
6.2 US Hemp Derivatives Market Revenue Share, By Type (2018 and 2027)
6.3 Hemp-Derived CBD
6.4 Hemp Seed Oil
6.5 Hemp Fiber
7. US Hemp Derivatives Market – By Application
7.2 US Hemp Derivatives Market Revenue Share, by Application (2018 and 2027)
7.3 Food & Beverages
7.5 Personal Care
8. Company Profiles
8.1 Colorado Hemp Works, LLC
8.2 Hempco Food and Fiber Inc. (Hempco Canada Superfoods)
8.3 Bell Flavors & Fragrances Inc.
8.4 Canada Hemp Foods Ltd.
8.5 Z-Company B.V.
For more information about this report visit https://www.researchandmarkets.com/r/b9eo4